AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05513612
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to package insert
Trial: NCT02408146
Drug: parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
Trial: NCT02227446
Drug: Vancomycin antibiotic powder
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
Trial: NCT02538965
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
Trial: NCT02457351
Drug: Roniciclib (BAY 1000394)
RxNorm normalized name: Roniciclib
DrugBank: Roniciclib (DB12974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose
Trial: NCT02457351
Drug: Itraconazole (Sporanox)
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
Trial: NCT00968578
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 125 mg iv pre-operatively
Trial: NCT00406640
Drug: Desvenlafaxine succinate sustained-release (DVS SR)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
Trial: NCT00406640
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
Trial: NCT00544128
Drug: lamivudine, abacavir , ritonavir, atazanavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
Trial: NCT00544128
Drug: emtricitabine, tenofovir, ritonavir, atazanavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
Trial: NCT04294264
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03968861
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled xenon gas given via purposely designed ventilator
Trial: NCT02461121
Drug: cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
Trial: NCT02461121
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
Trial: NCT02461121
Drug: Ara-C
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
Trial: NCT02461121
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/d for 5days
Trial: NCT02461121
Drug: anti-lymphocyte globulin
RxNorm normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-2 mg/kg/d for 4 days
Trial: NCT03140436
Drug: sodium bicarbonate powders with grain size 65 µm
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium bicarbonate powders with grain size 65 µm
Trial: NCT03140436
Drug: sodium bicarbonate powders with grain size 40 µm
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium bicarbonate powders with grain size 40 µm
Trial: NCT00112151
Drug: LowT
RxNorm normalized name: Flowtuss
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
Trial: NCT00112151
Drug: HighT
RxNorm normalized name: kaolin light
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
Trial: NCT01476215
Drug: Paracetamol fast dissolution suspension
RxNorm normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01476215
Drug: Paracetamol slow dissolution suspension
RxNorm normalized name: Slow-Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01476215
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00408369
Drug: DB289
RxNorm normalized name: Pafuramidine
DrugBank: Pafuramidine (DB06532)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04575428
Drug: Splanchnic nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous splanchnic nerve block
Trial: NCT00778466
Drug: metformin hydrochloride 1000 mg tablets
RxNorm normalized name: metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02082054
Drug: Atropine 0.24 mg
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side
Trial: NCT00648908
Drug: Fampridine-SR
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10 mg, BID
Trial: NCT02911948
Drug: Insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected s.c. / subcutaneously (under the skin) once daily
Trial: NCT02911948
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected s.c. / subcutaneously (under the skin) once daily
Trial: NCT02866253
Drug: DHEA
RxNorm normalized name: DHEA
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
Trial: NCT01745263
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU/d
Trial: NCT01745263
Drug: Omega 3 fatty acids
RxNorm normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratio EPA:DHA = 1:2~1 g/d
Trial: NCT04755543
Drug: LP002
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
Trial: NCT04755543
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m2 IV on Day 1, Q2W
Trial: NCT04089605
Drug: dexamethasone implant
RxNorm normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravitreal dexamethasone implant injections in vitrectomized patients with DME
Trial: NCT04089605
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal ranibizumab injections in vitrectomized patients with DME
Trial: NCT03919890
Drug: ONO-7684
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
Trial: NCT02372292
Drug: intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
Trial: NCT02426983
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
Trial: NCT03990766
Drug: Saline Nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactose delivered via high-volume, low-pressure nasal saline irrigation
Trial: NCT02060201
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02060201
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02060201
Drug: Saxagliptin/Dapagliflozin FDC
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00872716
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg single-dose Quetiapine XR
Trial: NCT03026504
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 milligrams oral Baricitinib daily for 52 weeks
Trial: NCT00092586
Drug: MK0653, ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02742649
Drug: Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous elution from the ocular insert. This is an active control arm.
Trial: NCT02742649
Drug: Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous elution from the ocular insert. This is an active control arm.
Trial: NCT02742649
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5% timolol drops twice daily.
Trial: NCT04424433
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
Trial: NCT00457054
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: starting dose 600 mg increase as tolerated
Trial: NCT01847638
Drug: Prolensa (bromfenac 0.07%)
RxNorm normalized name: Prolensa
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
Trial: NCT01847638
Drug: Ilevro (nepafenac 0.3%)
RxNorm normalized name: Ilevro
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
Trial: NCT04451434
Drug: Danicopan
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02467452
Drug: FlF/VI + Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366834
Drug: Casopitant (GW679769) oral tablets
RxNorm normalized name: maropitant Oral Tablet
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366834
Drug: Casopitant (GW679769) intravenous
RxNorm normalized name: casopitant
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366834
Drug: Dexamethasone intravenous
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00366834
Drug: Ondansetron oral tablets
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01259492
Drug: Ritalin LA 20 mg
RxNorm normalized name: Ritalin LA 20 MG 24HR Extended Release Oral Capsule
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
Trial: NCT01259492
Drug: Ritalin LA 30 mg
RxNorm normalized name: Ritalin LA 30 MG 24HR Extended Release Oral Capsule
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
Trial: NCT00764972
Drug: Sorafenib and Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.
Trial: NCT02016417
Drug: A combination of Gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Trial: NCT00079612
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800mg daily (2x 400mg tabs)
Trial: NCT02299908
Drug: TAP block with Bupivacaine at 0.25%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
Trial: NCT00667758
Drug: Cetrorelix
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-5 mg s.c. on days 1-5
Trial: NCT03588767
Drug: Vitamin D3 + anabolic substance
RxNorm normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
Trial: NCT03716063
Drug: Jianpi Huatan dispensing granule
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once a day in the morning and evening, every month for a course of treatment, a total of three courses
Trial: NCT05002192
Drug: Eucalyptol, Limonene and Pinene Enteric Soft Capsule
DrugBank: Eucalyptol (DB03852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
Trial: NCT05002192
Drug: Ambroxol injection
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
Trial: NCT05002192
Drug: Other oral mucolytic drugs
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
Trial: NCT00568789
Drug: Ramelteon, zolpidem and placebo
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3
Trial: NCT00399269
Drug: Recombinant Human Erythropoietin alpha
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017316
Drug: semaxanib
RxNorm normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017316
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04747574
Drug: EXO-CD24
RxNorm normalized name: exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride
DrugBank: Cantharidin (DB12328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
Trial: NCT00260741
Drug: Smoked Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00490373
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02778867
Drug: Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03623984
Drug: Gallium Dotatate
RxNorm normalized name: GALLIUM DOTATATE,GA-68
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
Trial: NCT03883022
Drug: with U-VANCO (vancomycin hydrochloride)
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gm or 2 gm mixed with autogenous cancellous bone graft
Trial: NCT03883022
Drug: without U-VANCO (vancomycin hydrochloride)
RxNorm normalized name: Vancomycin Hydrochloride
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no vancomycin added
Trial: NCT00854529
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sub-conjunctival injection of 1.25mg Bevacizumab
Trial: NCT01270672
Drug: 3,4-Methylenedioxymethamphetamine
RxNorm normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg per os, single dose
Trial: NCT01270672
Drug: carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg per os, single dose
Trial: NCT01935908
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00003546
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given IV
Trial: NCT03601416
Drug: Transplantation of mesenchymal stem cell
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg